Verified Peptide ReviewLast reviewed: 12 March 2026
Compound Profile · GH Releasing
CJC-1295
CJC-1295 is a stabilised, long-acting analog of GHRH. Two variants exist — with and without DAC. Used in research, not approved for human use.
LegalResearch onlyEvidenceStrongHuman useNot approved
8.6/ 10
Peptide Score
Evidence
Safety
Regulatory
Transparency
Quick verdict
Best understood as half of the CJC-1295 + Ipamorelin pairing. Used alone, results are more variable.
Reality check
What this isn't
- Not approved for human use — research-only context
- No regulator has approved human use
- Side-effect profile not fully characterised
- Educational only — not medical advice
Full CJC-1295 review
A long-acting GHRH analog.
Two main forms: CJC-1295 (with DAC) and Mod GRF 1-29 (without DAC).
Looking at alternatives?
Compounds with comparable research interest but different evidence, regulatory status, or risk profile.
Growth Hormone
CJC-1295 + Ipamorelin
4.6/ 5
A
Why consider it: Related research-interest profile.
View profileGH Releasing
Tesamorelin
4.4/ 5
A
Why consider it: Related research-interest profile.
View profileGH Secretagogue
Ipamorelin
4.3/ 5
A−
Why consider it: Related research-interest profile.
View profile